No Data
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
Repurchase assembly on November 6 | hsbc holdings, cosco shipping holdings, etc. have repurchased one after another, with hsbc holdings spending 0.271 billion Hong Kong dollars.
According to the disclosure documents filed by hkex on November 7, hsbc holdings (00005.HK), cosco shipping holdings (01919.HK), among others, repurchased shares.① hsbc holdings (00005.HK) repurchased 3.7528 million ordinary shares on November 5, involving 0.271 billion Hong Kong dollars, with a repurchase price per share ranging from 72.4 Hong Kong dollars to 72 Hong Kong dollars. ② cosco shipping holdings (01919.HK) repurchased 7.6695 million H shares on November 6, involving 94.3464 million Hong Kong dollars, with a repurchase price per share ranging from 12.64 Hong Kong dollars to 12.
essex bio-tech (01061.HK) spent 0.0996 million Hong Kong dollars to repurchase 0.04 million shares on November 6th.
On November 6, Gelonhui. Essex Bio-Tech (01061.HK) announced that on November 6, 2024, it spent 0.0996 million Hong Kong dollars to repurchase 0.04 million shares at a repurchase price of 2.48-2.5 Hong Kong dollars per share.
No Data
No Data